|Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR|
VM Corman, O Landt, M Kaiser, R Molenkamp, A Meijer, DKW Chu, ...
Eurosurveillance 25 (3), 2000045, 2020
|Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant|
J Lopez Bernal, N Andrews, C Gower, E Gallagher, R Simmons, ...
New England Journal of Medicine 385 (7), 585-594, 2021
|Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study|
D Nepogodiev, A Bhangu, JC Glasbey, E Li, OM Omar, JFF Simoes, ...
The Lancet 396 (10243), 27-38, 2020
|Commentary: Middle east respiratory syndrome coronavirus (mers-cov): announcement of the coronavirus study group|
RJ De Groot, SC Baker, RS Baric, CS Brown, C Drosten, L Enjuanes, ...
Journal of virology 87 (14), 7790-7792, 2013
|Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant|
N Andrews, J Stowe, F Kirsebom, S Toffa, T Rickeard, E Gallagher, ...
New England Journal of Medicine 386 (16), 1532-1546, 2022
|Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome|
T Kuiken, RAM Fouchier, M Schutten, GF Rimmelzwaan, ...
The Lancet 362 (9380), 263-270, 2003
|Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study|
E Miller, K Hoschler, P Hardelid, E Stanford, N Andrews, M Zambon
The Lancet 375 (9720), 1100-1108, 2010
|Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020|
A Singanayagam, M Patel, A Charlett, JL Bernal, V Saliba, J Ellis, ...
Eurosurveillance 25 (32), 2001483, 2020
|Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction|
VM Corman, I Eckerle, T Bleicker, A Zaki, O Landt, M Eschbach-Bludau, ...
Eurosurveillance 17 (39), 2012
|SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses|
W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ...
Cell 185 (3), 467-484. e15, 2022
|COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study|
VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ...
The Lancet 397 (10286), 1725-1735, 2021
|Community transmission and viral load kinetics of the SARS-CoV-2 delta (B. 1.617. 2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal …|
A Singanayagam, S Hakki, J Dunning, KJ Madon, MA Crone, A Koycheva, ...
The lancet infectious diseases 22 (2), 183-195, 2022
|Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012|
A Bermingham, MA Chand, CS Brown, E Aarons, C Tong, C Langrish, ...
Eurosurveillance 17 (40), 2012
|Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study|
S de Lusignan, J Dorward, A Correa, N Jones, O Akinyemi, ...
The Lancet Infectious Diseases 20 (9), 1034-1042, 2020
|Unexpected receptor functional mimicry elucidates activation of coronavirus fusion|
AC Walls, X Xiong, YJ Park, MA Tortorici, J Snijder, J Quispe, E Cameroni, ...
Cell 176 (5), 1026-1039. e15, 2019
|SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)|
VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ...
The Lancet 397 (10283), 1459-1469, 2021
|Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza|
KG Nicholson, AE Colegate, A Podda, I Stephenson, J Wood, E Ypma, ...
The Lancet 357 (9272), 1937-1943, 2001
|Mapping the human genetic architecture of COVID-19|
Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ...
Nature 600 (7889), 472-477, 2021
|Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial|
JL Bresson, C Perronne, O Launay, C Gerdil, M Saville, J Wood, ...
The Lancet 367 (9523), 1657-1664, 2006
|Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 season|
A Meijer, A Lackenby, O Hungnes, B Lina, S Van Der Werf, B Schweiger, ...
Emerging infectious diseases 15 (4), 552, 2009